Crizotinib in the treatment of lymphoma

Crizotinib has shown remarkable results in the treatment of lymphoma, especially anaplastic lymphoma kinase (ALK)-positive lymphoma. This drug is a multi-target protease inhibitor that blocks the growth and spread of tumor cells by inhibiting the activity of ALK. For patients with ALK-positive lymphoma, the emergence of crizotinib is undoubtedly a new treatment hope.

Crizotinib has not only achieved remarkable results in the treatment of advanced non-small cell lung cancer, but its application in the treatment of lymphoma has also gradually attracted attention. Lymphoma is a malignant tumor originating from the lymphatic system, and ALK-positive lymphoma is a rare type. However, it is against this rare type of lymphoma that crizotinib has shown its unique efficacy.

One study investigated crizotinib in 36 children and adolescents with ALK-positive ALCL or unresectable IMT. Among 22 patients with ALK-positive ALCL, 86% (19 of 22 patients) achieved a complete response (17 patients) or a partial response (2 patients), with a mean duration of 3.6 months.

Among the 14 patients with ALK-positive IMT, 86% (12 of 14 patients) achieved a complete response (5 patients) or a partial response (7 patients), with a mean duration of 14.8 months.

In general, crizotinib, as a new type of targeted therapy, has shown significant efficacy in the treatment of ALK-positive lymphoma. Although there are some potential side effects, under the guidance of doctors, crizotinib is expected to bring better therapeutic effects and quality of life to lymphoma patients.